X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CIPLA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CIPLA DIVIS LABORATORIES/
CIPLA
 
P/E (TTM) x 38.4 40.5 94.9% View Chart
P/BV x 6.2 3.7 167.3% View Chart
Dividend Yield % 0.7 0.5 158.2%  

Financials

 DIVIS LABORATORIES   CIPLA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
CIPLA
Mar-18
DIVIS LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,142663 172.2%   
Low Rs533479 111.3%   
Sales per share (Unadj.) Rs146.6189.0 77.5%  
Earnings per share (Unadj.) Rs33.017.6 187.8%  
Cash flow per share (Unadj.) Rs38.434.0 112.9%  
Dividends per share (Unadj.) Rs10.003.00 333.3%  
Dividend yield (eoy) %1.20.5 227.3%  
Book value per share (Unadj.) Rs222.8176.7 126.1%  
Shares outstanding (eoy) m265.47805.12 33.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.73.0 189.1%   
Avg P/E ratio x25.332.5 78.1%  
P/CF ratio (eoy) x21.816.8 129.9%  
Price / Book Value ratio x3.83.2 116.3%  
Dividend payout %30.317.1 177.5%   
Avg Mkt Cap Rs m222,318459,724 48.4%   
No. of employees `00010.823.6 45.6%   
Total wages/salary Rs m4,56126,901 17.0%   
Avg. sales/employee Rs Th3,616.06,446.1 56.1%   
Avg. wages/employee Rs Th423.81,139.4 37.2%   
Avg. net profit/employee Rs Th814.9600.0 135.8%   
INCOME DATA
Net Sales Rs m38,915152,193 25.6%  
Other income Rs m1,1343,577 31.7%   
Total revenues Rs m40,049155,769 25.7%   
Gross profit Rs m12,61728,264 44.6%  
Depreciation Rs m1,42513,228 10.8%   
Interest Rs m131,142 1.2%   
Profit before tax Rs m12,31317,470 70.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m3,5432,501 141.7%   
Profit after tax Rs m8,77014,166 61.9%  
Gross profit margin %32.418.6 174.6%  
Effective tax rate %28.814.3 201.0%   
Net profit margin %22.59.3 242.1%  
BALANCE SHEET DATA
Current assets Rs m45,351108,141 41.9%   
Current liabilities Rs m6,50738,322 17.0%   
Net working cap to sales %99.845.9 217.6%  
Current ratio x7.02.8 247.0%  
Inventory Days Days12797 130.6%  
Debtors Days Days9574 127.9%  
Net fixed assets Rs m21,160109,411 19.3%   
Share capital Rs m5311,610 33.0%   
"Free" reserves Rs m58,625140,682 41.7%   
Net worth Rs m59,156142,292 41.6%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m67,832228,606 29.7%  
Interest coverage x926.816.3 5,688.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 86.2%   
Return on assets %12.96.7 193.4%  
Return on equity %14.810.0 148.9%  
Return on capital %20.810.0 209.3%  
Exports to sales %032.8 0.0%   
Imports to sales %21.80-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35951,691 62.6%   
Fx outflow Rs m9,04221,033 43.0%   
Net fx Rs m23,31730,658 76.1%   
CASH FLOW
From Operations Rs m7,75914,628 53.0%  
From Investments Rs m-4,783-8,540 56.0%  
From Financial Activity Rs m-3,142-3,855 81.5%  
Net Cashflow Rs m-1662,431 -6.8%  

Share Holding

Indian Promoters % 52.0 16.0 325.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.8 12.2 96.7%  
FIIs % 19.0 23.7 80.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.2 26.2 65.6%  
Shareholders   31,796 161,166 19.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ORCHID PHARMA LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS